KRAS and thyroid cancer: The limitation of the current study may be that we failed to prove the clinical utility of BRAF, KRAS, NRAS, and TERT promoter mutation as circulating markers in early-staged thyroid cancers distinguishing from benign thyroid lesions or healthy individuals.